Passage Bio Inc.

PBFT02 showed increased CSF PGRN levels and reduced plasma NfL levels in FTD-GRN patients. Dose 2, 50% lower than Dose 1, is being evaluated. Passage Bio extended cash runway to 1Q 2027 by reducing expenses and transitioning to outsourced analytical testing. 12-month data from Dose 1 and interim data from Dose 2 expected in 2H 2025.

Passage Bio reported PBFT02's Phase 1/2 upliFT-D trial data for FTD-GRN, showing increased CSF PGRN and reduced plasma NfL levels. Dose 2, 50% lower, is being evaluated. Cash runway extended to 1Q 2027 via operational adjustments. 12-month Dose 1 data and Dose 2 interim data expected in 2H 2025.

Passage Bio reports interim data from the upliFT-D study showing PBFT02 increased CSF PGRN levels and reduced plasma NfL levels in FTD-GRN patients. Plans to evaluate a lower Dose 2, report 12-month data in 2H 2025, and seek regulatory feedback in 1H 2026. Extended cash runway to 1Q 2027 by reducing expenses and transitioning to outsourced analytical testing.

Passage Bio reports PBFT02's Phase 1/2 upliFT-D trial updates for FTD-GRN, showing increased CSF PGRN and reduced plasma NfL levels. Plans include Dose 2 evaluation, extending cash runway to 1Q 2027, and initiating FTD-C9orf72 dosing in 1H 2025. Manufacturing process scaled up for efficiency.

Lynx1 Capital Management Lp increased its stake in Passage Bio by purchasing 373,645 shares at $0.65 each, totaling $242,869.25, now owning 9,256,953 shares valued at ~$6,017,019.45. Institutional investors hold 53.48% of Passage Bio, with several analysts setting 'buy' ratings and price targets up to $13.00. Passage Bio develops gene therapies for CNS diseases.

DelveInsight's report on the Gene and Cell Therapies Targeting CNS Disorders market forecasts growth to 2034, highlighting key companies and therapies, including Bayer AG's Phase Ib clinical trial success for Parkinson's disease and uniQure's positive trends in Huntington's disease trials. The market, valued at approximately USD 1 billion in 2021, is expected to surge due to increasing disease prevalence and pipeline product launches.